Bone-active agents that decrease bone turnover (the anti-resorptive agents) have been, to
date, the most thoroughly studied pharmacological agents for the management of
osteoporosis in a variety of populations–postmenopausal, male, and glucocorticoid-induced
osteoporosis–and have received both Food and Drug Administration (FDA) and Committee
for Medicinal Products for Human Use (CHMP) as well as other worldwide registrations for
the management of these conditions. While the mechanisms of action of 'anti-resorptives' as …